Thank you to everyone who visited our booth at the PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2025! Our team enjoyed meeting you and demonstrating the innovative enFuse® On-Body Delivery System. Contact us to learn more: https://t.co/jsxLschR1y

We are excited to announce a new partnership with Incyte to develop and commercialize specific assets in Incyte’s portfolio with the enFuse® On-Body Delivery System! Learn more here: https://t.co/Cm2TzdqblK

Between the pipeline of talent, economic incentives, and the wide network of support across the #lifesciences ecosystem, Enable Injections is proud to call #Cincinnati home! Read more about this growing industry in the region from the @BusinessCourier: https://t.co/S4gfxCzy1l

#KidneyWk, hosted by the American Society of Nephrology (ASN) is only a month away! If you’re attending, stop by Booth 202 for a demonstration of our enFuse system or contact us to set up a meeting: https://t.co/jsxLschR1y #DrugDelivery #largevolume #enFuse

#PODD2025 is only a month away! If you’re attending, stop by Booth 701 for a demonstration of our enFuse system or contact us to set up a meeting: https://t.co/jsxLschR1y #DrugDelivery #largevolume #subcutaneousdelivery #enFuse

Be sure to catch our session “Addressing Large-Volume Subcutaneous Delivery Challenges with enFuse: A Patient- and Provider-Centric Solution” at PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2025, Oct 21. #PDA #drugdelivery #enFuse

Are you ready to make an impact and create meaningful change in a growing company and in the lives of patients? Check out the opportunity here: https://t.co/jcIZsmhevV ​ #Hiring #enFuse

The future of patient care lies not only in the drugs we discover, but in how we deliver them. The latest edition of @ONdrugDelivery is here, focusing on wearable injectors and featuring the innovative enFuse drug delivery system! Read the full article: https://t.co/xcXM9zhcoO

We’re excited to announce the enFuse System has been approved by Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ANVISA)! . Read the full announcement here: https://t.co/aw8nzkes0Q #enFuse #drugdelivery #subcu

By allowing mobility during administration, the enFuse empowers patients to live their normal lives while receiving their medication. Learn more about the enFuse on our website: https://t.co/zk0bV0Pvxu #enFuse #drugdelivery #subcutaneous #selfadministration #innovativetechnology

The U.S. FDA has approved Apellis Pharmaceuticals’ treatment for complement 3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), severe and rare kidney diseases, for patients 12 and older: https://t.co/hDx7dQCGiw

Why is SC delivery a game-changer for biopharma? Download our whitepaper to discover how wearable technology can simplify drug delivery while also potentially reducing burden on healthcare systems and improving safety & efficacy: https://t.co/BZw2Cihqmz #drugdelivery #enFuse

We’re proud to announce the enFuse Syringe Transfer System is now registered in the UK! This registration comes after the enFuse recently received CE Mark approval in the EU. We look forward to bringing our technology to patients around the world! #drugdelivery #enFuse

Discover how #subcutaneousdelivery unlocks value and drives sales growth in our white paper published by @FierceBiotech: https://t.co/BZw2Cihqmz Learn how switching from IV to SC #drugdelivery can be a viable, effective and low risk way to set products apart.

Join our Director of Business Development, Bruce Ernest, next week in Boston, MA, June 16-19 for the Bio International Convention! Request a meeting with Bruce here:  https://t.co/CSSnyxbXOr #BioInternational #drugdelivery #enFuse

Thank you to everyone who visited our booth at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting! Read more about data presented at ASCO featuring the enFuse technology in this Fierce Pharma article: https://t.co/ffc085hJtJ #enFuse #ASCO2025 #subcutaneousdelivery

New positive data presented at #ASCO25 and published in @JCO_ASCO analyzed our enFuse drug delivery technology with an investigational subcutaneous #MultipleMyeloma combination therapy. Read the full @Sanofi press release: https://t.co/279Mb3iFGO

At Enable, we’re working to shift the narrative about large-volume subcutaneous delivery through education and data. Our VP of Medical Affairs Mehul Desai sat down with pharmaphorum to discuss recent survey findings. Read more: https://t.co/7IBYIMYpe7 #drugdelivery #enFuse

Join us at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting next week in Chicago, Illinois, May 30 - June 3! Visit Booth 17152 to learn more about the innovative enFuse drug delivery system or request a meeting: https://t.co/jsxLschR1y #ASCO #drugdelivery #enFuse

Read our white paper published by @FiercePharma to understand the forces driving the shift to subcutaneous delivery: https://t.co/mnatb6XVnE #drugdelivery #subcutaneousdelivery #enFuse